Narrative Review: Risk-Benefit Hydroxychloroquine and Chloroquine in COVID-19
Chloroquine (CQ) and Hydroxychloroquine (HCQ) are highly prescribed as medications for COVID-19 infection, although no robust or convincing data has yet been published about the efficacy in COVID-19 patients. Therefore, risk and benefit assessment are necessary for decision to prescribe these drugs...
Guardado en:
Autor principal: | Jarir At Thobari |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Universitas Gadjah Mada
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fb02e7f7df494a719045340e55b8dbab |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical Efficacy of Hydroxychloroquine or Chloroquine in Patients with COVID-19: An Umbrella Review
por: Kavous Shahsavarinia, et al.
Publicado: (2021) -
Incidence of and risk factors for chloroquine and hydroxychloroquine retinopathy in Thai rheumatologic patients
por: Tangtavorn N, et al.
Publicado: (2016) -
Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions
por: Mayra Souza Botelho, et al.
Publicado: (2021) -
Immunity-Boosting Natural Herbs to Combat COVID-19 Pandemic: A Narrative Review
por: Saurabh Nimesh, et al.
Publicado: (2021) -
Correlation between Biophysical Properties of Niosomes Elaborated with Chloroquine and Different Tensioactives and Their Transfection Efficiency
por: Myriam Sainz-Ramos, et al.
Publicado: (2021)